Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Torque teno virus | 3 | 2019 | 73 | 2.07 | Why? |
| DNA Virus Infections | 3 | 2019 | 88 | 2.05 | Why? |
| Transplantation, Homologous | 8 | 2019 | 757 | 1.61 | Why? |
| DNA, Viral | 9 | 2019 | 2521 | 1.53 | Why? |
| Hematopoietic Stem Cell Transplantation | 7 | 2019 | 2426 | 0.98 | Why? |
| Glucuronidase | 1 | 2020 | 103 | 0.78 | Why? |
| Cytomegalovirus | 6 | 2019 | 600 | 0.74 | Why? |
| Plasma | 2 | 2019 | 1809 | 0.72 | Why? |
| Respiratory System | 3 | 2021 | 3213 | 0.70 | Why? |
| Cytomegalovirus Infections | 5 | 2019 | 667 | 0.56 | Why? |
| Viral Load | 8 | 2021 | 15850 | 0.41 | Why? |
| Vancomycin | 3 | 2019 | 328 | 0.39 | Why? |
| Point-of-Care Testing | 2 | 2021 | 2782 | 0.36 | Why? |
| Staphylococcus aureus | 3 | 2019 | 844 | 0.30 | Why? |
| Staphylococcal Infections | 3 | 2019 | 1099 | 0.25 | Why? |
| Viremia | 3 | 2019 | 1020 | 0.24 | Why? |
| RNA, Viral | 6 | 2021 | 32276 | 0.23 | Why? |
| Stem Cell Transplantation | 2 | 2017 | 531 | 0.23 | Why? |
| Immunoassay | 4 | 2021 | 4485 | 0.23 | Why? |
| Saliva | 1 | 2018 | 4679 | 0.23 | Why? |
| Immunologic Tests | 2 | 2021 | 445 | 0.22 | Why? |
| Phagocytes | 2 | 2019 | 180 | 0.19 | Why? |
| Water Microbiology | 1 | 2021 | 248 | 0.18 | Why? |
| Nasopharynx | 4 | 2021 | 10224 | 0.18 | Why? |
| Blood | 1 | 2018 | 274 | 0.17 | Why? |
| Carrier State | 2 | 2020 | 2100 | 0.17 | Why? |
| Antigens, Viral | 4 | 2021 | 6298 | 0.16 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.16 | Why? |
| Bacteremia | 2 | 2019 | 1372 | 0.16 | Why? |
| Cell Wall | 1 | 2016 | 62 | 0.16 | Why? |
| Cloxacillin | 1 | 2015 | 14 | 0.15 | Why? |
| Transplantation Conditioning | 1 | 2018 | 323 | 0.15 | Why? |
| Antibody Affinity | 1 | 2020 | 1078 | 0.14 | Why? |
| Immunoglobulin M | 3 | 2020 | 9091 | 0.14 | Why? |
| Aged | 18 | 2021 | 215776 | 0.14 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.14 | Why? |
| Hospitals, Community | 1 | 2018 | 475 | 0.13 | Why? |
| Interferon-gamma | 2 | 2021 | 2711 | 0.13 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.13 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.13 | Why? |
| Flow Cytometry | 2 | 2019 | 2393 | 0.12 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.12 | Why? |
| Reagent Kits, Diagnostic | 2 | 2020 | 2149 | 0.12 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2019 | 676 | 0.12 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.12 | Why? |
| Male | 23 | 2021 | 367725 | 0.12 | Why? |
| Adult | 18 | 2021 | 244371 | 0.12 | Why? |
| Female | 23 | 2021 | 380317 | 0.11 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Kinetics | 4 | 2021 | 3238 | 0.11 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.11 | Why? |
| Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.11 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.11 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.10 | Why? |
| Endocarditis, Bacterial | 1 | 2015 | 344 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.10 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.10 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 11367 | 0.09 | Why? |
| Ambulatory Care Facilities | 1 | 2020 | 2063 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1573 | 0.09 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.09 | Why? |
| Humans | 35 | 2021 | 930598 | 0.09 | Why? |
| Child | 7 | 2021 | 70012 | 0.09 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.09 | Why? |
| Transplant Recipients | 3 | 2018 | 4982 | 0.08 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.08 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.08 | Why? |
| Nursing Homes | 2 | 2021 | 4155 | 0.08 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.08 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.08 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 13720 | 0.08 | Why? |
| Biomarkers | 4 | 2021 | 23361 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.07 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.06 | Why? |
| Infant | 3 | 2021 | 30274 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Copper Sulfate | 1 | 2021 | 19 | 0.06 | Why? |
| Sodium Bicarbonate | 1 | 2021 | 54 | 0.05 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Citric Acid | 1 | 2021 | 116 | 0.05 | Why? |
| Immunity | 2 | 2021 | 2651 | 0.05 | Why? |
| Binding Sites, Antibody | 1 | 2020 | 466 | 0.05 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.05 | Why? |
| Microbial Sensitivity Tests | 2 | 2019 | 2886 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.04 | Why? |
| Point-of-Care Systems | 2 | 2021 | 2955 | 0.04 | Why? |
| Glycopeptides | 1 | 2019 | 199 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Trachea | 1 | 2021 | 894 | 0.04 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.04 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.04 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Nose | 1 | 2021 | 1093 | 0.04 | Why? |
| Microarray Analysis | 1 | 2016 | 262 | 0.03 | Why? |
| Genotyping Techniques | 1 | 2016 | 360 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Endocytosis | 1 | 2016 | 451 | 0.03 | Why? |
| DNA | 1 | 2018 | 778 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.03 | Why? |
| Microbial Viability | 1 | 2016 | 406 | 0.03 | Why? |
| Geography | 1 | 2018 | 1801 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2017 | 830 | 0.03 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Family Characteristics | 1 | 2021 | 2551 | 0.03 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Spain | 2 | 2018 | 15545 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Qualitative Research | 1 | 2020 | 4337 | 0.02 | Why? |
| Antiviral Agents | 2 | 2017 | 41703 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Risk Factors | 1 | 2019 | 71621 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.00 | Why? |
Albert's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(135)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_